ATE501151T1 - Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren - Google Patents

Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren

Info

Publication number
ATE501151T1
ATE501151T1 AT08713287T AT08713287T ATE501151T1 AT E501151 T1 ATE501151 T1 AT E501151T1 AT 08713287 T AT08713287 T AT 08713287T AT 08713287 T AT08713287 T AT 08713287T AT E501151 T1 ATE501151 T1 AT E501151T1
Authority
AT
Austria
Prior art keywords
treatment
disorders
disease
useful
compounds
Prior art date
Application number
AT08713287T
Other languages
English (en)
Inventor
John Debenham
Jeffrey Hale
Pei Huo
Christina Madsen-Duggan
Thomas Walsh
Lin Yan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE501151T1 publication Critical patent/ATE501151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
AT08713287T 2007-01-31 2008-01-25 Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren ATE501151T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89860207P 2007-01-31 2007-01-31
US90569007P 2007-03-08 2007-03-08
PCT/US2008/001042 WO2008094476A1 (en) 2007-01-31 2008-01-25 Substituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators

Publications (1)

Publication Number Publication Date
ATE501151T1 true ATE501151T1 (de) 2011-03-15

Family

ID=39371009

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08713287T ATE501151T1 (de) 2007-01-31 2008-01-25 Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren

Country Status (8)

Country Link
US (1) US7999107B2 (de)
EP (1) EP2109615B1 (de)
JP (1) JP2010516810A (de)
AT (1) ATE501151T1 (de)
AU (1) AU2008211259A1 (de)
CA (1) CA2676167A1 (de)
DE (1) DE602008005405D1 (de)
WO (1) WO2008094476A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279846A1 (en) * 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
KR101119719B1 (ko) 2009-06-15 2012-03-09 경희대학교 산학협력단 피라노피란-1,8-다이온을 함유하는 천식치료제
DK2493871T3 (da) * 2009-10-30 2014-11-10 Prestwick Chemical Sas Nye oximderivater samt deres anvendelse som allosteriske modulatorer af metabotropiske glutamatreceptorer
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
KR101326557B1 (ko) 2011-03-31 2013-11-08 주식회사종근당 카나비노이드 수용체〔ｃｂｉ〕길항제로서의 벤즈아미드 유도체
BR112014006220A2 (pt) 2011-09-16 2017-04-11 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
CN104619329B (zh) 2012-06-06 2018-01-26 卡莱克汀医疗有限公司 用于治疗与升高的诱导型一氧化氮合酶相关联的疾病的半乳糖‑鼠李糖半乳糖醛酸酯组合物
EP3133065A1 (de) 2015-08-21 2017-02-22 Merck Patent GmbH Verbindungen für optisch aktive vorrichtungen
HUE048032T2 (hu) * 2015-10-15 2020-05-28 Jiangsu Hengrui Medicine Co Oxaspiro-származék, elõállítási eljárása és alkalmazásai gyógyszerekben
EP3363786A1 (de) 2017-02-15 2018-08-22 Merck Patent GmbH Verbindungen für optisch aktive vorrichtungen
EP3363793A1 (de) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobe verbindungen zur herstellung von optisch aktiven vorrichtungen
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
IL291783A (en) * 2019-10-02 2022-06-01 Domain Therapeutics ep4 prostaglandin e2 receptor antagonists
KR20230012616A (ko) 2020-05-20 2023-01-26 에이엠오 아일랜드 광학 활성 장치에 사용하기 위한 아자쿠마린 및 아자티오쿠마린 유도체
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain
AR127618A1 (es) 2021-11-29 2024-02-14 Bayer Ag Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas
US20250066377A1 (en) * 2021-12-17 2025-02-27 Pretzel Therapeutics, Inc. Amino chromen-2-one modulators of polrmt
CN115260092B (zh) * 2022-08-23 2023-08-25 山东京博生物科技有限公司 一种2-氯烟酰胺及其n取代衍生物的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5140031A (en) 1989-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Pyranyl cyanoguanidine derivatives
US5061813A (en) 1990-04-02 1991-10-29 E. R. Squibb & Sons, Inc. Substituted cyanoimino benzopyranes
GB9102804D0 (en) 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
JPH04282353A (ja) 1991-03-11 1992-10-07 Yoshitomi Pharmaceut Ind Ltd ベンゾピラン類縁体
JP2647762B2 (ja) 1991-07-30 1997-08-27 吉富製薬株式会社 ベンゾピラン類縁体
US5463059A (en) 1992-11-10 1995-10-31 E. R. Squibb & Sons, Inc. Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives
IL109229A0 (en) 1993-05-11 1994-07-31 Bristol Myers Squibb Co Heterocyclic compounds and processes for the preparation of pyranyl cyanoguanidine derivatives using the same
EP0764159B1 (de) 1994-06-10 2000-08-09 Smithkline Beecham Plc C-4 amid substituierte verbindungen und deren verwendung als therapeutische mittel
WO1998009969A1 (en) 1996-09-05 1998-03-12 Astra Pharmaceuticals Ltd. Novel aryl-pyridazines
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
EP0895994A3 (de) 1997-08-05 1999-12-15 Hoechst Marion Roussel Deutschland GmbH Sulfonamid-substituierte Pyranopyridine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9914255D0 (en) 1999-06-18 1999-08-18 Lilly Forschung Gmbh Pharmaceutical compounds
EP1274700B1 (de) 2000-01-03 2004-11-17 Pharmacia Corporation Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JO2352B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Compounds for the treatment of non-adaptation of the bottom of the uterus
DE60139506D1 (de) 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
EP1453828A2 (de) 2001-10-16 2004-09-08 AstraZeneca AB Azabicyclische verbindungen zur behandlung des fibromyalgie-syndroms
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
BRPI0215050B8 (pt) 2001-12-21 2021-05-25 Anormed Inc compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
AU2003257145B2 (en) * 2002-08-02 2008-11-13 Merck Sharp & Dohme Corp. Substituted furo (2,3-b) pyridine derivatives
JP4282353B2 (ja) 2003-03-27 2009-06-17 シチズンセイミツ株式会社 時計用文字板
US7183413B2 (en) 2003-04-11 2007-02-27 Taigen Biotechnology Aminoquinoline compounds
AU2004252109B2 (en) 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US20050129610A1 (en) 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
WO2005042697A2 (en) 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
DE602004024814D1 (de) 2003-11-04 2010-02-04 Merck & Co Inc Substituierte naphthyridinonderivate
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
TW200838516A (en) * 2007-01-31 2008-10-01 Merck & Co Inc Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators

Also Published As

Publication number Publication date
EP2109615B1 (de) 2011-03-09
JP2010516810A (ja) 2010-05-20
DE602008005405D1 (de) 2011-04-21
US7999107B2 (en) 2011-08-16
US20080207666A1 (en) 2008-08-28
CA2676167A1 (en) 2008-08-07
AU2008211259A1 (en) 2008-08-07
EP2109615A1 (de) 2009-10-21
WO2008094476A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
ATE501151T1 (de) Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren
WO2008024284A3 (en) Sulfonylated piperazines as cannabinoid-1 receptor modulators
WO2007136607A3 (en) Substituted esters as cannabinoid-1 receptor modulators
ATE375349T1 (de) Substituierte furo(2,3-b)pyridin derivate
MXPA05013583A (es) Derivados de 3-alquil y 3-alquenilazetidina sustituidos.
DE60334787D1 (de) Substituierte amide
EP1492784A4 (de) Substituierte 2,3-diphenylpyridine
WO2003082190A3 (en) Spirocyclic amides as cannabinoid receptor modulators
JO2482B1 (en) Amide compounds by replacement
WO2004058145A3 (en) Substituted amides
WO2003063781A3 (en) Substituted imidazoles as cannabinoid receptor modulators
WO2004029204A3 (en) Substituted pyrimidines
ATE452890T1 (de) Substituierte naphthyridinonderivate
WO2003086288A3 (en) Bicyclic amides
WO2005027837A3 (en) Substituted sulfonamides
WO2003007887A3 (en) Substituted imidazoles as cannabinoid receptor modulators
NO20063381L (no) CB1 modulatorforbindelser
ECSP088477A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
MX2021001379A (es) Compuestos de 1-metil-4-[(4-fenilfenil)sulfonilmetil]ciclohexanol y 1-metil-4-[[4-(2-piridil)fenil]sulfonilmetil]ciclohexanol y su uso terapeutico.
JP2020503332A5 (de)
WO2007064566A3 (en) Heterocycle-substituted 3-alkyl azetidine derivatives
CN107735401A (zh) 取代二氢吡咯并吡唑衍生物
ATE457985T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
WO2006041797A3 (en) Acyclic hydrazides as cannabinoid receptor modulators
ATE471322T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties